A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA

Simply Wall St.05-04

AdvertisementWhy AMT-130’s MHRA Meeting Matters for uniQure Stock uniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632983456?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-04 02:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632983456","market":"hk","top_or_hot":-1,"title":"A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy AMT-130’s MHRA Meeting Matters for uniQure Stock uniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-04 02:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy AMT-130’s MHRA Meeting Matters for uniQure Stock uniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4097","symbol_name":"系统软件","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr","article_id":"2632983456","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632983456","pubTimestamp":1777832184,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why AMT-130’s MHRA Meeting Matters for uniQure Stock\nuniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting with the UK’s Medicines and Healthcare products Regulatory Agency.\nThe company now plans to file a Marketing Authorization Application in the third quarter of 2026, using three year Phase I/II data that reported a 75% slowing of disease progression at the high dose, with a generally well tolerated and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4097":"系统软件","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","QURE":"uniQure N.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4554":"元宇宙及AR概念","BK4581":"高盛持仓","BK4084":"特种房地产投资信托","AMT":"美国电塔","PRGS":"Progress Software Corporation","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","BK4219":"电信塔房地产信托","BK4585":"ETF&股票定投概念"},"translate_title":"AMT-130 MHRA监管进展后uniQure(QURE)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"QURE":1.5,"AMT":1.5},"content_text":"AdvertisementWhy AMT-130’s MHRA Meeting Matters for uniQure Stock uniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting with the UK’s Medicines and Healthcare products Regulatory Agency. The company now plans to file a Marketing Authorization Application in the third quarter of 2026, using three year Phase I/II data that reported a 75% slowing of disease progression at the high dose, with a generally well tolerated and manageable safety profile. See our latest analysis for uniQure. The regulatory progress on AMT-130 comes as uniQure’s share price trades at US$19.13, with a 30 day share price return of 11.48% partly offset by a 90 day share price decline of 22.55%. Meanwhile, the 1 year total shareholder return of 29.52% contrasts with weaker multi year total shareholder returns. If advances in Huntington’s disease gene therapy have your attention, it can be worth scanning other healthcare names too, including 33 healthcare AI stocks. With uniQure valued at about US$1.21b and the share price sitting at US$19.13 after mixed recent returns, are investors getting Huntington’s disease potential at a discount, or is the market already pricing in future growth? Most Popular Narrative: 50.3% Undervalued At a last close of $19.13 against a narrative fair value of $38.48, the current price sits well below what this widely followed model implies.  With strong cash reserves of over $400 million, uniQure is described as being in a solid position to fund operations through the launch of AMT-130 and to support other key data readouts, which this narrative suggests could influence earnings positively.  Read the complete narrative. Want to see what, according to this narrative, could turn that cash pile and Huntington’s program into a higher fair value? The narrative refers to rapid revenue expansion, shifting margins, and a steep future earnings multiple. Curious which assumptions contribute most to that 50.3% gap? Result: Fair Value of $38.48 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on AMT-130 clearing regulatory hurdles without major delays and on uniQure managing revenue pressure and manufacturing handoffs without fresh setbacks. Find out about the key risks to this uniQure narrative. Another Way to Look at uniQure’s Valuation The narrative fair value suggests uniQure looks undervalued, but the P/B ratio tells a tougher story. At 6.1x book value versus 2.3x for the wider US Biotechs group, the shares trade at a rich premium to the industry, even if they screen cheaper than some peers at 20.9x. Is that extra pricing power a cushion, or is it a source of downside risk if expectations reset? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:QURE P/B Ratio as at May 2026Next Steps Mixed signals on value and sentiment so far? With both risks and potential rewards in play, review the data yourself and weigh the 1 key reward and 4 important warning signs. Looking For More Investment Ideas? If uniQure has sharpened your focus, do not stop here. Use data driven stock ideas to widen your watchlist and avoid missing opportunities elsewhere.  Target potential mispricing by scanning companies that combine quality fundamentals with attractive pricing through the 50 high quality undervalued stocks. Prioritize capital protection by reviewing the 69 resilient stocks with low risk scores and seeing which businesses carry lower risk scores. Spot sturdier balance sheets that might handle shocks better by searching the solid balance sheet and fundamentals stocks screener (44 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632983456","isCrawlerRequest":true}